Deviating from a guidance [Design Issues]

posted by Pharma_88 – India, 2024-05-21 10:32 (416 d 16:54 ago) – Posting: # 24005
Views: 3,947

Dear Helmut,

Thank you. Yes for For submission study, will definitely initiate CC with FDA. Since this is a pilot study where main objective is to assess the possibility of the single dose administration effect on pharmacokinetic as well as safety. So any possibility to conduct parallel design study? if yes, how it will be designed?

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,434 posts in 4,931 threads, 1,674 registered users;
72 visitors (0 registered, 72 guests [including 25 identified bots]).
Forum time: 03:26 CEST (Europe/Vienna)

For every expert there is an equal and opposite expert.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5